IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

8.79USD +1.03% (+0.09)

Over 6M: +62.5%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

4 6 8
Mar Apr May Jun Jul Aug Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Operating Income: -118.4M Q4 '23 — Operating Income: -121.3M Q1 '24 — Operating Income: -117.7M Q2 '24 — Operating Income: -101.9M Q3 '24 — Operating Income: -89.1M Q4 '24 — Operating Income: -86.6M Q1 '25 — Operating Income: -121.2M Q2 '25 — Operating Income: -113.8M Q3 '25 — Operating Income: -94.9M Q4 '25 — Operating Income: -73.5M Q1 '26 — Operating Income: -81M Q2 '26 — Operating Income: -51.9M -100M -75M -50M -25M 0
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Gross Profit Operating Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.4
SBC / sales 14.4%
OE margin -105.6%
Oper. margin -92.7%
ROIC -54.2%
Accruals -2.8%
Gross margin 48.4%
EBITDA margin -88.6%
FCF margin -91.2%
OCF margin -81.3%
Profit margin -89.1%
ROA -31.6%
ROCE -37.3%
ROE -39.3%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

2.9
EV/Sales 11.3×
EV/OE -10.7×
P/C 13.4×
P/B 5.4×
FCF yield -7.4%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.0
ND/EBITDA 0.081
Cash runway 1.0 yr
Cash / Debt 297.7×
Debt / Eq 0.0014×
Debt payback 0.0 yr
Quick ratio 3.8×
F-score 2.2 pts
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

5.2
Sales/sh Y/Y +9.1%
Sales Q/Q +65.7%
Shares change +23.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.